The development of
a concise asymmetric synthesis of the antiviral
development candidate letermovir is reported, proceeding in >60%
yield
over a total of seven steps from commercially available materials.
Key to the effectiveness of this process is a novel cinchonidine-based
PTC-catalyzed aza-Michael reaction to configure the single stereocenter.
A divergent and regioselective synthesis of either 3-substituted benzisoxazoles or 2-substituted benzoxazoles from readily accessible ortho-hydroxyaryl N-H ketimines is described. The reaction proceeds in two distinct pathways through a common N-Cl imine intermediate: (a) N-O bond formation to form benzisoxazole under anhydrous conditions and (b) NaOCl mediated Beckmann-type rearrangement to form benzoxazole, respectively. The reaction path also depends on the electronic nature of the aromatic ring, with the electron-rich aromatic rings favoring the rearrangement and the electron-deficient rings favoring the N-O bond formation. A Beckmann-type rearrangement mechanism via net [1,2]-aryl migration for the formation of 2-substituted benzoxazole is proposed.
The synthesis of
the potent anti-HIV investigational treatment islatravir is described.
The key step in this synthesis is a highly enantioselective catalytic
asymmetric alkynylation of a ketone. This reaction is a rare example
of the asymmetric addition of an alkyne nucleophile to a ketone through
ligand-accelerated catalysis that was performed on a greater than
100 g scale. By leveraging a multienzyme cascade, a highly diastereoselective
aldol-glycosylation was used to complete the target in eight steps.
A weak Brønsted acid-catalyzed asymmetric guanidine aza-conjugate addition reaction has been developed. C-symmetric, dual hydrogen-bond donating bistriflamides are shown to be highly effective in activating α,β-unsaturated esters toward the intramolecular addition of a pendant guanidinyl nucleophile. Preliminary mechanistic investigation, including density functional theory calculations and kinetics studies, support a conjugate addition pathway as more favorable energetically than an alternative electrocyclization pathway. This methodology has been successfully applied to the synthesis of the 3,4-dihydroquinazoline-containing antiviral, Letermovir, and a series of analogues.
Two new routes to
a pyrimidyl tetrazole intermediate are described.
The first-generation route featured an iron-catalyzed cross-coupling
between 4-butenylmagnesium bromide and a 4-chloropyrimidine derivative
to afford an alkene-bearing pyrimidine intermediate. A subsequent
intramolecular Heck cyclization afforded the desired bicyclic core,
which was subsequently converted to the corresponding carboxylic acid
via hydroboration and oxidation. This route was rapidly defined and
used to prepare the initial 0.3 kg of the pyrimidyl tetrazole intermediate,
which supported early toxicology and clinical studies of a drug candidate.
A second-generation, eight-step route to the pyrimidyl tetrazole intermediate
was defined and demonstrated on multikilogram scale in a 21% overall
yield. The key transformation in this sequence was a copper(I) mediated
cyclization of an iodopyrimidine, affording the bicyclic core of the
target in quantitative yield. Due to the larger scale involved for
the second-generation approach, significant process safety evaluation
was undertaken for a number of steps in this route, and the highlights
of these studies are presented.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.